Hajime Okuyama

Direttore/Membro del Consiglio presso HanaVax, Inc.

Finance

Health Technology

Profilo

Hajime Okuyama is currently a Director at HanaVax, Inc. He was previously a Manager at Fast Track Initiative, Inc.

Società	Posizione	Inizio
HanaVax, Inc. HanaVax, Inc. BiotechnologyHealth Technology HanaVax, Inc. develops nasal vaccine against infectious diseases. It develops pneumococcal nasal vaccine to prevent pneumonia, sepsis and otitis media. The company was founded by Hosei Ou on December 27, 2017 and is headquartered in Tokyo, Japan.	Direttore/Membro del Consiglio	-

Società	Posizione	Fine
Fast Track Initiative, Inc. Fast Track Initiative, Inc. Investment ManagersFinance Fast Track Initiative, Inc. (FTI) is a Venture Capital firm, a subsidiary of Life Science Management, Inc. founded in 2004 by Koichi Ashida and Hiromichi Kimura. Fast Track Initiative, Inc. is headquartered in Tokyo with additional office in the Unites States.	Investitore di Private Equity	-

Attive

Inattive

Società quotate in Borsa

Aziende private

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Aziende private	2
Fast Track Initiative, Inc. Fast Track Initiative, Inc. Investment ManagersFinance Fast Track Initiative, Inc. (FTI) is a Venture Capital firm, a subsidiary of Life Science Management, Inc. founded in 2004 by Koichi Ashida and Hiromichi Kimura. Fast Track Initiative, Inc. is headquartered in Tokyo with additional office in the Unites States.	Finance
HanaVax, Inc. HanaVax, Inc. BiotechnologyHealth Technology HanaVax, Inc. develops nasal vaccine against infectious diseases. It develops pneumococcal nasal vaccine to prevent pneumonia, sepsis and otitis media. The company was founded by Hosei Ou on December 27, 2017 and is headquartered in Tokyo, Japan.	Health Technology